Georgia Marie Beasley

Georgia Marie Beasley is an Associate Professor of Surgery and Medicine at Duke University School of Medicine, with active faculty membership in the Duke Cancer Institute. Her clinical practice focuses on surgical oncology for melanoma treatment, while her research bridges innate immunity and anti-tumor responses. She earned her MD (2008) and MHS in clinical research (2010) from Duke, followed by general surgery residency (2008-2015) and a surgical oncology fellowship at Ohio State University (2015-2017).

• Education:
  • Duke University School of Medicine (MD, 2008)
  • Duke University (MHS, 2012)
  • Duke University (B.A., 2001)

Dr. Beasley's research centers on immunologic aspects of melanoma, particularly oncolytic viral therapy and innate immune mechanisms in tumor response. She leads over 10 therapeutic clinical trials for melanoma, including innovative intratumoral treatments, and has authored more than 100 publications on these topics. Her work explores the intersection of tumor microenvironment dynamics, immune status measurement, and microbiome interactions in cancer progression.

Recent publications highlight her focus on circulating tumor DNA applications (2025), GLI2 signaling in immune evasion (2025), and national trends in pediatric stage III melanoma management (2025). These reflect broader research priorities in melanoma staging accuracy, immune-based therapies, and translational oncology.

• Scientific Awards:
  • Society of Surgical Oncology Young Investigator Award
  • NIH K08 Mentored Physician Scientist Award
  • Melanoma Research Alliance Grant
  • Duke Medical School Alpha Omega Alpha Honor
  • American Society for Clinical Investigation Young Physician-Scientist Award

Dr. Beasley secures substantial funding through grants including a 2024-2029 National Cancer Institute award for Duke Research Training in Surgical Oncology, a 2024-2026 NIH grant for older adult melanoma decision-making, and a 2023-2026 Department of Defense grant measuring immune status to prevent recurrence. She also collaborates on training programs at the intersection of cancer immunology and microbiome bioinformatics.